Effect of resveratrol on cancer progression through the *REG III* expression pathway in head and neck cancer cells

SHINJI MIKAMI¹, ICHIRO OTA¹, TAKASHI MASUI¹, ASAKO ITAYA-HIRONAKA²,
RYOGO SHOBATAKE², HIDEYUKI OKAMOTO³, SHIN TAKASAWA² and TADASHI KITAHARA¹

Departments of ¹Otolaryngology-Head and Neck Surgery and ²Biochemistry, Nara Medical University, Kashihara, Nara 634-8522; ³Department of Otolaryngology, Nara City Hospital, Nara 630-8305, Japan

Received June 18, 2016; Accepted August 12, 2016

DOI: 10.3892/ijo.2016.3664

Abstract. Identification of reliable markers of chemo- and radiosensitivity and the key molecules that enhance the susceptibility of head and neck squamous cell carcinoma (HNSCC) to anticancer treatments is highly desirable. Previously, we have reported that *regenerating gene (REG) III* expression was such a marker associated with an improved survival rate for HNSCC patients. In the present study, we investigated the stimulators for induction of *REG III* expression using *REG III* promoter assay in HNSCC cells transfected with *REG III* promoter vector. We tested inflammatory cytokines, growth factors, polyphenols, PPAR γ activator of thiazolidinediones, and histone deacetylase inhibitors, and found that 3,4',5-trihydroxy-*trans*-stilbene (resveratrol) significantly increased the *REG III* promoter activity and the mRNA levels of *REG III* in HNSCC cells. Moreover, we demonstrated the effect of resveratrol on cancer cell progression, such as cell proliferation, chemo- and radiosensitivity and cancer invasion of HNSCC cells. Resveratrol significantly inhibited cell growth, enhanced chemo- and radiosensitivity, and blocked cancer invasion of HNSCC cells. These data suggested that resveratrol could inhibit cancer progression through the *REG III* expression pathway in HNSCC cells.

Introduction

Worldwide, >600,000 people are newly diagnosed with head and neck cancer each year (1-3), and head and neck squamous cell carcinoma (HNSCC) is one of the 10 most common malignancies in the world and also known for clinical progression and poor prognosis. The cancer-related death is mainly caused by metastasis of tumors to regional lymph nodes and distant

organs. Many patients are diagnosed in advanced stages, in which standard treatment is a combination of platinum-based chemotherapy, radiation, and/or surgery (3-6). As primary treatments for advanced HNSCC, recently there have been advances in definitive chemoradiotherapy (CRT) instead of extended surgery. Despite the recent progress of the treatment for improving locoregional control in HNSCC patients, that for recurrence and metastatic control remains insufficient (7,8), indicating that there is a continued need for improved treatment strategies. As an obvious risk factor of HNSCC, continuous irritation by tobacco and alcohol abuse is well-known (3,7,9). Furthermore, recent studies have shown that HNSCC is associated with human papillomavirus (HPV) infection, especially at oropharyngeal region (10-12). In contrast, there is no reliable marker for the other sites of HNSCC. Therefore, the key molecules that enhance chemo- and radiosensitivity in HNSCC and identification of reliable markers for predicting the recurrence and metastasis would be desirable to improve the prognosis of HNSCC patients.

It has been reported that inflammation is an important phase in tumor progression, and many cancers originate from inflammation. In connection with digestive organs, many studies have demonstrated that the human *regenerating gene (REG)* expression is observed in chronic inflammation and in tumors (13-20). *Reg* was first identified in regenerating pancreatic islets in 1988 (21). *Reg* family belongs to the lectin superfamily and encodes five small, secreted proteins (13,22-25). *Reg* family proteins are classified into four subfamilies: type I, II, III, and IV; the human *REG* family consists of five members: *REG Ia*, *REG Ib*, *REG III*, *hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP)* and *REG IV* (13,20,22,26-29). *REG* family protein has been shown to play roles, not only in normal tissue regeneration (30,31), but also in the development of various malignancies (32-43). Indeed, *REG* expression has been reported to be associated with progression of cancers such as esophageal, gastric, lung, and colorectal cancer (32-39,43). Considering that oral and pharyngeal cavities are often exposed to chronic inflammatory factors such as tobacco, alcohol and mechanical stimuli, it is possible that *REG* expression is associated with HNSCC. Recently we reported that *REG III* expression was associated with prognosis of HNSCC patients (44). In addition, we demonstrated that *REG III*

Correspondence to: Dr Ichiro Ota, Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
E-mail: iota@naramed-u.ac.jp

Key words: polyphenol, regenerating gene family, head and neck squamous cell carcinoma, chemosensitivity, radiosensitivity

regulated cell proliferation and chemo- and radiosensitivity in HNSCC *in vitro*. These results suggested that enhancement of *REG III* expression increased chemo- and radiosensitivity, and improved prognosis of HNSCC patients. In the present study, we investigated the stimulator for the enhancement of *REG III* expression in HNSCC cells. Furthermore, we first demonstrate that the stimulator can effect proliferation, invasion, and chemo- and radiosensitivity in HNSCC cells.

Materials and methods

Cell culture and reagents. Human HNSCC cells, FaDu and HSC-4, were employed in this study. FaDu cells were provided by the American Type Culture Collection (Manassas, VA, USA). HSC-4 cells were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) and 100 U/ml penicillin G and 100 μ g/ml streptomycin and 250 ng/ml amphotericin B (Gibco™ Antibiotic-Antimycotic; Gibco). The cells were maintained in a 5% CO₂/95% air, humidified atmosphere at 37°C. Interleukin (IL)-6 and tumor necrosis factor- α (TNF- α) were purchased from Roche Applied Science (Indianapolis, IN, USA). IL-1 β , IL-8, IL-11, IL-13, IL-17, IL-22, hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), cardiotrophin, oncostatin M, interferon (IFN)- β , quercetin, 3,4',5-trihydroxy-*trans*-stilbene (resveratrol), fisetin, genistein, chlorogenic acid, estradiol, bisphenol A, sodium butyrate were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Dexamethasone (Dx) and o-dianisidine were from MP Biomedicals (Santa Ana, CA, USA). Daidzein was purchased from Fujicco Co., Ltd. (Kobe, Japan), epigallocatechin gallate from Enzo Life Sciences, Inc. (Framingdale, NY, USA), curcumin from Nacalai Tesque, Inc. (Tokyo Japan), ciglitazone and troglitazone from Cayman Chemical Co. (Ann Arbor, MI, USA), trichostatin A from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan), and phorbol 12-myristate 13-acetate from Sigma-Aldrich (St. Louis, MO, USA).

Isolation of stable transformants with *REG III* promoter vector. The reporter constructs were prepared by inserting the 5'-flanking regions of human *REG III* (-1,985 to +87 of *REG III* gene) (28) upstream of a luciferase reporter gene in pGL4.17 vector (luc2/Neo; Promega Corp., Madison, WI, USA). The *REG III* promoter vector was introduced into FaDu cells by electroporation using Gene Pulser Xcell™ (Bio-Rad, Hercules, CA, USA) (44), after which the stable transformants were selected in DMEM supplemented with 10% FBS and 500 μ g/ml Geneticin® (Invitrogen) for 3 weeks. Introduction of the *REG III* promoter/luciferase construct in the Geneticin®-resistant cells was confirmed by PCR.

Promoter assays. The *REG III* promoter vector was introduced into FaDu cells as described above. The stable transformants were seeded in 24-well plates at an initial density of 1x10⁵ cells/well. After a 24-h incubation, the cells were treated with 20 ng/ml of IL-1 β , 20 ng/ml of IL-6, 10 nM

of IL-8, 100 ng/ml of IL-11, 100 ng/ml of IL-13, 1 μ g/ml of IL-17, 20 ng/ml of IL-22, 50 ng/ml of HGF, 10 nM of bFGF, 10 nM of EGF, 20 ng/ml of TNF- α , 20 ng/ml of cardiotrophin, 20 ng/ml of oncostatin M, 100 nM of Dx, 50 ng/ml of IFN- β , 50 μ M of quercetin, 20 μ M of resveratrol, 20 μ M of fisetin, 50 μ M of genistein, 60 μ M of chlorogenic acid, 200 μ M of o-dianisidine, 10 nM of okadaic acid, 10 μ M of daidzein, 100 nM of epigallocatechin gallate, 1 μ M of estradiol, 10 μ M of bisphenol A, 12.5 μ M of curcumin, 50 μ M of ciglitazone, 30 μ M of troglitazone, 1 μ M of trichostatin A, 1 mM of sodium butyrate, or 50 nM of phorbol 12-myristate 13-acetate. After a 24-h treatment, the medium was aspirated from each well and washed with PBS, and the cells were harvested with 100 μ l of lysis buffer (0.1 M potassium phosphate, pH 8.8, 0.2% Triton X-100). The cells were processed for luciferase assay using a Pica Gene luminescence kit (TOYO B-Net Co., Ltd., Tokyo, Japan) as described (45-50).

Quantitative real-time RT-PCR. Total RNA was isolated using RNeasy Protect® Cell Mini Kit (Qiagen, Hilden, Germany) from FaDu cells. cDNA was reverse transcribed from 0.5-2 μ g samples of total RNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) as described (44,45,47-51). cDNA was subjected to PCR with the following primers, synthesized and prepared by Nihon Gene Research Laboratories, Inc. (NGRL; Sendai, Japan): β -actin (NM_001101) sense, 5'-GCGAGAAGATGACCCAGA-3' and antisense, 5'-CAGAGGCGTACAGGGATA-3'; *REG III* (AB161037) sense 5'-GAATATTCTCCCCAACTG-3' and antisense, 5'-GAGAAAAGCCTGAAATGAAG-3'.

Real-time PCR was performed using KAPA SYBR FAST qPCR Master Mix (Kapa Biosystems, Boston, MA, USA) and Thermal Cycler Dice Real-Time System (Takara Bio, Inc., Otsu, Japan) as described (43-45,47-51). PCR was performed with an initial step of 3 min at 95°C followed by 40 cycles of 3 sec at 95°C, 20 sec at 60°C. The level of target mRNA was normalized to the mRNA level of β -actin as an internal standard.

Cell proliferation assay. Cell proliferation activity was assessed by using a Cell Counting Kit-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium, monosodium salt (WST-8) cleavage; Dojindo Laboratories, Kumamoto, Japan] as described (43,44,47,50,52). Cells were plated in 96-well plates and incubated for 24 h. Initial density of FaDu and HSC-4 cells was 3x10³ cells/well. After 24 h, 30 μ M of resveratrol was added to each well and incubated for 24, 48 and 72 h, while dimethylsulfoxide (DMSO; Sigma-Aldrich) was added as a control. At 24 h of incubation, medium was changed and resveratrol was removed from each well. After addition of 10 μ l of WST-8 solution, the cells were incubated for another 2 h. The absorbance of each well at 450 nm (reference wavelength at 620 nm) was read by using a Multiskan™ FC Microplate Photometer (Thermo Fisher Scientific, Waltham, MA, USA). Each measurement was repeated at least four times on each cell line.

Chemo- and radiotherapy for cultured cells. Cells were exposed to 0, 5 and 10 Gy radiation using a MBR-1520R (Hitachi, Ltd., Tokyo, Japan) operating at 150 kV and 20 mA as

Figure 1. Screening of activator(s) for human *REG III* transcription. Human *REG III* promoter (-1,985 to +87 of *REG III* gene) was introduced into FaDu human HNSCC cells and stable transformants were selected (clone #1 and #2). (A) Effects of cytokines and growth factors on activation of *REG III* gene promoter of (a) clone #1, (b) clone #2 in FaDu cells. Cells were transfected with the *REG III* gene reporter plasmids and treated as follows: C, no addition as a control; 1, IL-1 β (20 ng/ml); 2, IL-6 (20 ng/ml); 3, IL-8 (10 nM); 4, IL-11 (100 ng/ml); 5, IL-13 (100 ng/ml); 6, IL-17 (1 μ g/ml); 7, IL-22 (20 ng/ml); 8, HGF (50 ng/ml); 9, bFGF (10 nM); 10, EGF (10 nM); 11, TNF- α (20 ng/ml); 12, cardiotrophin (20 ng/ml); 13, oncostatin M (20 ng/ml); 14, Dx (100 nM); 15, IL-6 + Dx; 16, IFN- β (50 ng/ml). The relative promoter activity was calculated by dividing the promoter activity of unstimulated cells (column 1). Data are expressed as means $\pm$ SE for each group. * P <0.05. (B) Effects of polyphenols, epigallocatechin gallate, PPAR γ activator of thiazolidinediones, and histone deacetylase inhibitor on activation of *REG III* gene promoter of (a) clone #1, (b) clone #2 in FaDu cells. Cells were transfected with the *REG III* gene reporter plasmids and treated as follows: C, no addition as a control; 17, quercetin (50 μ M); 18, resveratrol (20 μ M); 19, fisetin (20 μ M); 20, genistein (50 μ M); 21, chlorogenic acid (60 μ M); 22, o-dianisidine (200 μ M); 23, okadaic acid (10 nM); 24, daidzein (10 μ M); 25, epigallocatechin gallate (100 nM); 26, estradiol (1 μ M); 27, bisphenol A (10 μ M); 28, curcumin (12.5 μ M); 29, ciglitazone (50 μ M); 30, troglitazone (30 μ M); 31, trichostatin A (1 μ M); 32, sodium butyrate (1 mM); 33, phorbol 12-myristate 13-acetate (50 nM). The promoter activity was calculated by dividing the promoter activity of unstimulated cells (column 1). Data are expressed as means $\pm$ SE for each group. * P <0.05. *REG*, regenerating gene; HNSCC, head and neck squamous cell carcinoma; IL, interleukin; HGF, hepatocyte growth factor; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; TNF- α , tumor necrosis factor- α ; Dx, dexamethasone; IFN, interferon; SE, standard error; resveratrol, 3,4',5-trihydroxy-*trans*-stilbene.

described (44), which delivered the dose at 0.8 Gy/min. Chemotherapy involved the application of cisplatin (Nihon Kayaku Co., Tokyo, Japan) to the cultures at a concentration of 0, 1.0, 3.0 or 10 μ M as described (44).

As for chemo- and radiosensitivity, the cell viability was assessed using WST-8 cleavage. Cells were plated in 96-well plates and incubated for 24 h. Initial density of FaDu cells was 3×10^3 cells/well, and of HSC-4 cells 1×10^3 cells/well. After 24 h, 30 μ M of resveratrol were added to each well, while DMSO was added as a control, and incubated for 48 h. For radiotherapy, they were then irradiated at 0, 5, or 10 Gy respectively. For chemotherapy, cisplatin (0-10 μ M) was added to cultures. Following incubation for additional 72 h, the absorbance of each well at 450 nm (reference wavelength at 620 nm) was read as described above. Each measurement was repeated at least four times on each cell line.

Invasion assay. Invasion assays were performed using 24-well Matrigel-coated Transwells (BD Biosciences, Bedford, MA, USA). A total of 4×10^4 cells of FaDu and HSC-4 were suspended in 200 μ l of serum-free DMEM and placed in the top chambers, and 700 μ l of DMEM containing 10% FBS were added to the bottom chambers. After 48 h of incubation at 37°C, non-invading cells were removed from the top of

the Matrigel with a cotton swab, while invading cells on the bottom surface of the filter were fixed in 4% paraformaldehyde and stained with Giemsa (Sigma-Aldrich) for 10 min. The invading cells were then visualized at x200 magnification and counted in five fields for each filter.

Data analysis. Data were expressed as means $\pm$ standard error (SE). Statistical significant differences between groups were determined by Student's t-test using StatMate IV (Abacus Concepts, Berkeley, CA, USA). P <0.05 was considered significant.

Results

Activation of *REG III* gene promoters in FaDu cells. To investigate activators of *REG III* gene expression, we tested various stimulative substances in two clones of FaDu cells to which the *REG III* promoter vector was stably introduced (Fig. 1). Among these various stimulators, polyphenols such as resveratrol, genistein, daidzein, and histone deacetylase inhibitors such as sodium butyrate, significantly increased the *REG III* promoter activity (Fig. 1). We also tested the concentration-response relationship of resveratrol, genistein, daidzein, sodium butyrate for *REG III* promoter

Figure 2. The mRNA levels of *REG III* in FaDu cells treated without (no addition) or with resveratrol (10 μ M), or genistein (25 μ M), or daidzein (40 μ M), or sodium butyrate (2 mM). Data are expressed as the ratio of the number of target mRNA normalized by β -actin mRNA as means $\pm$ SE for each group (N=4). *P<0.05. *REG*, *regenerating gene*; resveratrol, 3,4',5-trihydroxy-*trans*-stilbene; SE, standard error.

activation, and found that the optimum concentration was 10 μ M (resveratrol), 25 μ M (genistein), 40 μ M (daidzein), and 2 mM (sodium butyrate) (data not shown).

Induction of *REG III* mRNA by candidate substances in FaDu cells. We examined mRNA levels of intrinsic *REG III* in FaDu cells by using real-time RT-PCR, after treating cells with 10 μ M resveratrol, 25 μ M genistein, 40 μ M daidzein, and 2 mM sodium butyrate, respectively. Resveratrol significantly increased the mRNA levels of *REG III* as compared with the others (Fig. 2). The combined addition of resveratrol with other candidates did not enhance, rather inhibited, the increment of *REG III* mRNA expression by resveratrol alone. It might be due to over-stimulation for the signaling pathway, and as a result, it might be higher concentrations for the effect, as reported by Liu *et al* (53). We also tested the concentration (0-100 μ M)-response relationship of *REG III* mRNA expression by resveratrol and found that the optimum concentration of resveratrol for *REG III* expression was 30 μ M (data not shown).

Effect of resveratrol on growth inhibition in HNSCC cells. We sought to evaluate the effect of resveratrol on cell proliferation of HNSCC cells, FaDu and HSC-4. In the proliferation assay using WST-8 cleavage, HNSCC cells (both FaDu and HSC-4 cells) treated with 30 μ M resveratrol showed a significant decrease in growth compared to untreated cells as a control. The resveratrol-induced growth inhibitory effect in HNSCC cells was time-dependent (Fig. 3).

Resveratrol enhances the chemo- and radiosensitivity of HNSCC cells. We measured the chemo- and radiosensitivity by addition of resveratrol to HNSCC cells using WST-8 cleavage. We found that HNSCC cells treated with resveratrol showed a significant increase in chemosensitivity (3.0 and 10 μ M of cisplatin) and radiosensitivity (5 and 10 Gy), as compared with cells treated with DMSO as a control (Fig. 4). Therefore, these results indicated that resveratrol enhances the chemo- and radiosensitivity of HNSCC cells.

Figure 3. Effect of resveratrol on cell proliferation in HNSCC cells. HNSCC cells treated without (no addition) or with resveratrol (30 μ M). Cell proliferation was determined by WST-8 assay at 24 h intervals up to 72 h in FaDu and HSC-4 cell lines. Data are shown as means $\pm$ SE. *P<0.05. Resveratrol, 3,4',5-trihydroxy-*trans*-stilbene; HNSCC, head and neck squamous cell carcinoma; SE, standard error.

Resveratrol blocks cancer invasion of HNSCC cells. We measured the invasive ability by addition of resveratrol to HNSCC cells using an invasion assay. We found that cells treated with resveratrol displayed significantly less invasive ability compared to that of the untreated cells as a control (Fig. 5).

Discussion

REG family proteins are believed to be associated with human digestive diseases such as inflammation and cancer (32-42,44,54,55). Recently, among human REG gene family, we have reported that *REG III* expression was associated with an improved survival rate for HNSCC patients, and *REG III* regulated cell proliferation and chemo- and radiosensitivity in HNSCC *in vitro* (44).

REG proteins are upregulated in many human cancers, and play their roles through several signaling pathways. According to previous reports, expression of REG was mainly induced by various inflammatory cytokines and exogenous growth factors (13). However, there is little information on these pathways. Some studies have demonstrated that cytokines such as IFN- γ , IL-6, IL-22, and TNF- α , enhance the expression of *REG I* (46,49,56-58). In addition, it is revealed that IL-8 regulates the expression of REG protein in gastric cancer cells (59) and that *REG I* acts as an anti-apoptotic factor through the STAT3 signaling pathway by increasing the expression and

Figure 4. Enhancement of chemo- and radiosensitivity in HNSCC cells by resveratrol. Cells were treated with (A and C) radiation at a dose of 0, 5 or 10 Gy, (B and D) 0, 1.0, 3.0, or 10 μM cisplatin. Thereafter each dish was incubated for additional 72 h. Cell viability was assessed using WST-8 assay. Data are shown as means ± SE. *P<0.05. HNSCC, head and neck squamous cell carcinoma; resveratrol, 3,4',5-trihydroxy-*trans*-stilbene; SE, standard error.

Figure 5. Inhibitory effect of resveratrol on cancer invasion in HNSCC cells. (A and B) Invading cells were visualized at x200 magnification. (C and D) The number of invading cells was counted in five fields for each filter. Results are expressed as means ± SE. *P<0.05. Resveratrol, 3,4',5-trihydroxy-*trans*-stilbene; HNSCC, head and neck squamous cell carcinoma; SE, standard error.

phosphorylation of Akt and Bad in gastric cancer cells (60). Furthermore, some studies demonstrated that PPARγ activator of thiazolidinediones such as ciglitazone and troglitazone inhibited *REG Ia* gene transcription (61). However, the

biological function and cell signaling pathway of *REG III* have not been elucidated.

In the present study, we investigated the stimulators for the induction of the expression of *REG III* in HNSCC *in vitro*.

In comparison with other type of *REG* family genes, expression of *REG III* was not induced by inflammatory cytokines, growth factors, and PPAR γ activator of thiazolidinediones. We first revealed that resveratrol, which is a naturally occurring polyphenol, significantly increased the *REG III* promoter activity and the mRNA levels of *REG III* in HNSCC cells.

Resveratrol is a natural compound present in fruits including red grapes, vegetables and beverages including wine that are part of the human diet (62-64). In recent years, many studies indicated that resveratrol is associated with antioxidant, anti-inflammatory, and anticarcinogenic effects (53,65,66). Concerning the anticarcinogenic potential of resveratrol, a number of studies have suggested that resveratrol modulates multiple cellular processes, including cell proliferation, apoptosis, inflammation, and angiogenesis (63,67-71). Several reports indicate that resveratrol inhibits proliferation of cancer cells by inhibiting cell cycle progression (72-75). Moreover, recent studies support the role of resveratrol in inhibition of cancer invasion (76,77). In the present study, we observed a reduction in cell growth rates and the enhancement of chemo- and radiosensitivity in HNSCC cells treated with resveratrol when compared with untreated cells as a control. Furthermore, the present study demonstrated that resveratrol blocked cancer invasion in HNSCC cells. These results were compatible to the anticarcinogenic effect in cells transfected with *REG III* (44). It can be presumed that resveratrol could enhance the chemo- and radiosensitivity and inhibit cancer progression through the *REG III* expression pathway in HNSCC cells. However, the downstream signaling pathway of *REG III* is still unresolved. The signaling pathway of how *REG III* reduces cell proliferation, blocks cancer invasion, and enhances the chemo- and radiosensitivity in HNSCC need to be investigated in future studies.

In summary, these data suggested that resveratrol can play an important role in the improvement of survival for HNSCC through the *REG III* expression pathway and can be a potential candidate for novel anticancer drugs for patients with HNSCC.

Acknowledgements

This study was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: E359-E386, 2015.
2. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. *CA Cancer J Clin* 64: 9-29, 2014.
3. Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. *Lancet* 371: 1695-1709, 2008.
4. Pignon JP, le Maître A, Maillard E and Bourhis J: MACH-NC Collaborative Group: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. *Radiother Oncol* 92: 4-14, 2009.
5. Ozer E, Grecula JC, Agrawal A, Rhoades CA, Young DC and Schuller DE: Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx. *Laryngoscope* 116: 607-612, 2006.
6. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, Geara FB, Klotch DW, Goepfert H and Peters LJ: Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 51: 571-578, 2001.
7. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, *et al*: Long-term follow-up of the RTOG 9501/intergroup phase III trial: Postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys* 84: 1198-1205, 2012.
8. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P, Lorenz RR and Carroll MA: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution. *J Clin Oncol* 24: 1064-1071, 2006.
9. Goldenberg D, Lee J, Koch WM, Kim MM, Trink B, Sidransky D and Moon CS: Habitual risk factors for head and neck cancer. *Otolaryngol Head Neck Surg* 131: 986-993, 2004.
10. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, *et al*: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. *J Clin Oncol* 26: 3128-3137, 2008.
11. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, *et al*: Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. *J Clin Oncol* 26: 3138-3146, 2008.
12. Shiboski CH, Schmidt BL and Jordan RC: Tongue and tonsil carcinoma: Increasing trends in the U.S. population ages 20-44 years. *Cancer* 103: 1843-1849, 2005.
13. Takasawa S: Regenerating gene (REG) product and its potential clinical usage. *Expert Opin Ther Targets* 20: 541-550, 2016.
14. Watanabe T, Yonekura H, Terazono K, Yamamoto H and Okamoto H: Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene. *J Biol Chem* 265: 7432-7439, 1990.
15. Fukui H, Kinoshita Y, Maekawa T, Okada A, Waki S, Hassan S, Okamoto H and Chiba T: Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. *Gastroenterology* 115: 1483-1493, 1998.
16. Higham AD, Bishop LA, Dimaline R, Blackmore CG, Dobbins AC, Varro A, Thompson DG and Dockray GJ: Mutations of RegI α are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. *Gastroenterology* 116: 1310-1318, 1999.
17. Shinozaki S, Nakamura T, Iimura M, Kato Y, Iizuka B, Kobayashi M and Hayashi N: Upregulation of Reg 1 α and GW112 in the epithelium of inflamed colonic mucosa. *Gut* 48: 623-629, 2001.
18. Ose T, Kadowaki Y, Fukuhara H, Kazumori H, Ishihara S, Udagawa J, Otani H, Takasawa S, Okamoto H and Kinoshita Y: Reg I-knockout mice reveal its role in regulation of cell growth that is required in generation and maintenance of the villous structure of small intestine. *Oncogene* 26: 349-359, 2007.
19. Zhang YW, Ding LS and Lai MD: Reg gene family and human diseases. *World J Gastroenterol* 9: 2635-2641, 2003.
20. Zhao J, Wang J, Wang H and Lai M: Reg proteins and their roles in inflammation and cancer of the human digestive system. *Adv Clin Chem* 61: 153-173, 2013.
21. Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y and Okamoto H: A novel gene activated in regenerating islets. *J Biol Chem* 263: 2111-2114, 1988.
22. Moriizumi S, Watanabe T, Unno M, Nakagawara K, Suzuki Y, Miyashita H, Yonekura H and Okamoto H: Isolation, structural determination and expression of a novel reg gene, human regI β . *Biochim Biophys Acta* 1217: 199-202, 1994.
23. Sanchez D, Figarella C, Marchand-Pinatel S, Bruneau N and Guy-Crotte O: Preferential expression of reg I β gene in human adult pancreas. *Biochem Biophys Res Commun* 284: 729-737, 2001.
24. Hervieu V, Christa L, Gouysse G, Bouvier R, Chayvialle JA, Bréchet C and Scoazec JY: HIP/PAP, a member of the reg family, is expressed in glucagon-producing enteropancreatic endocrine cells and tumors. *Hum Pathol* 37: 1066-1075, 2006.
25. Drickamer K: Two distinct classes of carbohydrate-recognition domains in animal lectins. *J Biol Chem* 263: 9557-9560, 1988.

26. Dusetti NJ, Frigerio JM, Fox MF, Swallow DM, Dagorn JC and Iovanna JL: Molecular cloning, genomic organization, and chromosomal localization of the human pancreatitis-associated protein (PAP) gene. *Genomics* 19: 108-114, 1994.
27. Lasserre C, Simon MT, Ishikawa H, Diriong S, Nguyen VC, Christa L, Vernier P and Brechot C: Structural organization and chromosomal localization of a human gene (HIP/PAP) encoding a C-type lectin overexpressed in primary liver cancer. *Eur J Biochem* 224: 29-38, 1994.
28. Nata K, Liu Y, Xu L, Ikeda T, Akiyama T, Noguchi N, Kawaguchi S, Yamauchi A, Takahashi I, Shervani NJ, *et al*: Molecular cloning, expression and chromosomal localization of a novel human *REG* family gene, *REG III*. *Gene* 340: 161-170, 2004.
29. Hartupree JC, Zhang H, Bonaldo MF, Soares MB and Dieckgraefe BK: Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: *Reg IV*. *Biochim Biophys Acta* 1518: 287-293, 2001.
30. Watanabe T, Yonemura Y, Yonekura H, Suzuki Y, Miyashita H, Sugiyama K, Moriizumi S, Unno M, Tanaka O and Kondo H: Pancreatic beta-cell replication and amelioration of surgical diabetes by *Reg* protein. *Proc Natl Acad Sci USA* 91: 3589-3592, 1994.
31. Asahara M, Mushiake S, Shimada S, Fukui H, Kinoshita Y, Kawanami C, Watanabe T, Tanaka S, Ichikawa A, Uchiyama Y, *et al*: *Reg* gene expression is increased in rat gastric enterochromaffin-like cells following water immersion stress. *Gastroenterology* 111: 45-55, 1996.
32. Macadam RC, Sarela AI, Farmery SM, Robinson PA, Markham AF and Guillou PJ: Death from early colorectal cancer is predicted by the presence of transcripts of the *REG* gene family. *Br J Cancer* 83: 188-195, 2000.
33. Violette S, Festor E, Pandrea-Vasile I, Mitchell V, Adida C, Dussaulx E, Lacorte JM, Chambaz J, Lacasa M and Lesuffleur T: *Reg IV*, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. *Int J Cancer* 103: 185-193, 2003.
34. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, Nakayama H and Yasui W: Expression and localization of *Reg IV* in human neoplastic and non-neoplastic tissues: *Reg IV* expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. *J Pathol* 207: 185-198, 2005.
35. Yonemura Y, Sakurai S, Yamamoto H, Endou Y, Kawamura T, Bandou E, Elnemr A, Sugiyama K, Sasaki T, Akiyama T, *et al*: *REG* gene expression is associated with the infiltrating growth of gastric carcinoma. *Cancer* 98: 1394-1400, 2003.
36. Dhar DK, Udagawa J, Ishihara S, Otani H, Kinoshita Y, Takasawa S, Okamoto H, Kubota H, Fujii T, Tachibana M, *et al*: Expression of regenerating gene I in gastric adenocarcinomas: Correlation with tumor differentiation status and patient survival. *Cancer* 100: 1130-1136, 2004.
37. Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S and Dieckgraefe BK: *Reg IV* activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. *Gastroenterology* 130: 137-149, 2006.
38. Hayashi K, Motoyama S, Koyota S, Koizumi Y, Wang J, Takasawa S, Itaya-Hironaka A, Sakuramoto-Tsuchida S, Maruyama K, Saito H, *et al*: *REG I* enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells. *Cancer Sci* 99: 2491-2495, 2008.
39. Zhou L, Zhang R, Wang L, Shen S, Okamoto H, Sugawara A, Xia L, Wang X, Noguchi N, Yoshikawa T, *et al*: Upregulation of *REG I* accelerates tumor progression in pancreatic cancer with diabetes. *Int J Cancer* 127: 1795-1803, 2010.
40. Fukui H, Fujii S, Takeda J, Kayahara T, Sekikawa A, Nanakin A, Suzuki K, Hisatsune H, Seno H, Sawada M, *et al*: Expression of *reg I* α protein in human gastric cancers. *Digestion* 69: 177-184, 2004.
41. Minamiya Y, Kawai H, Saito H, Ito M, Hosono Y, Motoyama S, Katayose Y, Takahashi N and Ogawa J: *REG1A* expression is an independent factor predictive of poor prognosis in patients with non-small cell lung cancer. *Lung Cancer* 60: 98-104, 2008.
42. Mauro V, Carette D, Chevallier D, Michiels JF, Segretain D, Pointis G and Sngas-Balas F: *Reg I* protein in healthy and seminoma human testis. *Histol Histopathol* 23: 1195-1203, 2008.
43. Kimura M, Naito H, Tojo T, Itaya-Hironaka A, Dohi Y, Yoshimura M, Nakagawara K, Takasawa S and Taniguchi S: *REG Ia* gene expression is linked with the poor prognosis of lung adenocarcinoma and squamous cell carcinoma patients via discrete mechanisms. *Oncol Rep* 30: 2625-2631, 2013.
44. Masui T, Ota H, Itaya-Hironaka A, Takeda M, Kasai T, Yamauchi A, Sakuramoto-Tsuchida S, Mikami S, Yane K, Takasawa S, *et al*: Expression of *REG III* and prognosis in head and neck cancer. *Oncol Rep* 30: 573-578, 2013.
45. Ota H, Tamaki S, Itaya-Hironaka A, Yamauchi A, Sakuramoto-Tsuchida S, Morioka T, Takasawa S and Kimura H: Attenuation of glucose-induced insulin secretion by intermittent hypoxia via down-regulation of *CD38*. *Life Sci* 90: 206-211, 2012.
46. Akiyama T, Takasawa S, Nata K, Kobayashi S, Abe M, Shervani NJ, Ikeda T, Nakagawa K, Unno M, Matsuno S, *et al*: Activation of *Reg* gene, a gene for insulin-producing β -cell regeneration: Poly(ADP-ribose) polymerase binds *Reg* promoter and regulates the transcription by autophagy(ADP-ribosylation). *Proc Natl Acad Sci USA* 98: 48-53, 2001.
47. Nakagawa K, Takasawa S, Nata K, Yamauchi A, Itaya-Hironaka A, Ota H, Yoshimoto K, Sakuramoto-Tsuchida S, Miyaoka T, Takeda M, *et al*: Prevention of *Reg I*-induced β -cell apoptosis by IL-6/dexamethasone through activation of *HGF* gene regulation. *Biochim Biophys Acta* 1833: 2988-2995, 2013.
48. Yamauchi A, Itaya-Hironaka A, Sakuramoto-Tsuchida S, Takeda M, Yoshimoto K, Miyaoka T, Fujimura T, Tsujinaka H, Tsuchida C, Ota H, *et al*: Synergistic activations of *REG Ia* and *REG Ib* promoters by IL-6 and glucocorticoids through JAK/STAT pathway in human pancreatic β cells. *J Diabetes Res* 2015: 173058, 2015.
49. Fujimura T, Fujimoto T, Itaya-Hironaka A, Miyaoka T, Yoshimoto K, Yamauchi A, Sakuramoto-Tsuchida S, Kondo S, Takeda M, Tsujinaka H, *et al*: Interleukin-6/STAT pathway is responsible for the induction of gene expression of *REG Ia*, a new auto-antigen in Sjgren's syndrome patients, in salivary duct epithelial cells. *Biochem Biophys Res Commun* 469: 69-74, 2015.
50. Tsujinaka H, Itaya-Hironaka A, Yamauchi A, Sakuramoto-Tsuchida S, Ota H, Takeda M, Fujimura T, Takasawa S and Ogata N: Human retinal pigment epithelial cell proliferation by the combined stimulation of hydroquinone and advanced glycation end-products via up-regulation of *VEGF* gene. *Biochem Biophys Res Commun* 469: 123-131, 2015.
51. Takasawa S, Kuroki M, Nata K, Noguchi N, Ikeda T, Yamauchi A, Ota H, Itaya-Hironaka A, Sakuramoto-Tsuchida S, Takahashi I, *et al*: A novel ryanodine receptor expressed in pancreatic islets by alternative splicing from type 2 ryanodine receptor gene. *Biochem Biophys Res Commun* 397: 140-145, 2010.
52. Ota H, Itaya-Hironaka A, Yamauchi A, Sakuramoto-Tsuchida S, Miyaoka T, Fujimura T, Tsujinaka H, Yoshimoto K, Nakagawara K, Tamaki S, *et al*: Pancreatic β cell proliferation by intermittent hypoxia via up-regulation of *Reg* family genes and *HGF* gene. *Life Sci* 93: 664-672, 2013.
53. Liu XJ, Bao HR, Zeng XL and Wei JM: Effects of resveratrol and genistein on nuclear factor κ B, tumor necrosis factor α and matrix metalloproteinase 9 in patients with chronic obstructive pulmonary disease. *Mol Med Rep* 13: 4266-4272, 2016.
54. Ogawa H, Fukushima K, Naito H, Funayama Y, Unno M, Takahashi K, Kitayama T, Matsuno S, Ohtani H, Takasawa S, *et al*: Increased expression of *HIP/PAP* and regenerating gene *III* in human inflammatory bowel disease and a murine bacterial reconstitution model. *Inflamm Bowel Dis* 9: 162-170, 2003.
55. Vives-Pi M, Takasawa S, Pujol-Autonell I, Planas R, Cabre E, Ojanguen I, Montraveta M, Santos AL and Ruiz-Ortiz E: Biomarkers for diagnosis and monitoring of celiac disease. *J Clin Gastroenterol* 47: 308-313, 2013.
56. Dusetti NJ, Mallo GV, Ortiz EM, Keim V, Dagorn JC and Iovanna JL: Induction of lithostathine/*reg* mRNA expression by serum from rats with acute pancreatitis and cytokines in pancreatic acinar AR-42J cells. *Arch Biochem Biophys* 330: 129-132, 1996.
57. Kinoshita Y, Ishihara S, Kadowaki Y, Fukui H and Chiba T: *Reg* protein is a unique growth factor of gastric mucosal cells. *J Gastroenterol* 39: 507-513, 2004.
58. Usami S, Motoyama S, Koyota S, Wang J, Hayashi-Shibuya K, Maruyama K, Takahashi N, Saito H, Minamiya Y, Takasawa S, *et al*: Regenerating gene I regulates interleukin-6 production in squamous esophageal cancer cells. *Biochem Biophys Res Commun* 392: 4-8, 2010.
59. Yoshino N, Ishihara S, Rumi MA, Ortega-Cava CF, Yuki T, Kazumori H, Takazawa S, Okamoto H, Kadowaki Y and Kinoshita Y: Interleukin-8 regulates expression of *Reg* protein in *Helicobacter pylori*-infected gastric mucosa. *Am J Gastroenterol* 100: 2157-2166, 2005.
60. Sekikawa A, Fukui H, Fujii S, Ichikawa K, Tomita S, Imura J, Chiba T and Fujimori T: *REG I* α protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. *Carcinogenesis* 29: 76-83, 2008.

61. Yamauchi A, Takahashi I, Takasawa S, Nata K, Noguchi N, Ikeda T, Yoshikawa T, Shervani NJ, Suzuki I, Uruno A, *et al*: Thiazolidinediones inhibit *REG Ia* gene transcription in gastrointestinal cancer cells. *Biochem Biophys Res Commun* 379: 743-748, 2009.
62. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y and Bonavida B: Resveratrol and cancer: Chemoprevention, apoptosis, and chemo-immunosensitizing activities. *Curr Med Chem Anticancer Agents* 3: 77-93, 2003.
63. Rubiolo JA, López-Alonso H, Martín-Vázquez V, Fol-Rodríguez NM, Vieytes MR, Botana LM and Vega FV: Resveratrol inhibits proliferation of primary rat hepatocytes in G0/G1 by inhibiting DNA synthesis. *Folia Biol (Praha)* 58: 166-172, 2012.
64. Frémont L: Biological effects of resveratrol. *Life Sci* 66: 663-673, 2000.
65. Kundu JK and Surh YJ: Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. *Cancer Lett* 269: 243-261, 2008.
66. Kovacic P and Somanathan R: Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety. *Oxid Med Cell Longev* 3: 86-100, 2010.
67. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M and Aggarwal BB: Resveratrol blocks interleukin-1 β -induced activation of the nuclear transcription factor NF- κ B, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. *Blood* 102: 987-995, 2003.
68. Liang YC, Tsai SH, Chen L, Lin-Shiau SY and Lin JK: Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34^{CDK2} kinases in colon carcinoma HT29 cells. *Biochem Pharmacol* 65: 1053-1060, 2003.
69. ElAttar TM and Virji AS: Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. *Anticancer Drugs* 10: 187-193, 1999.
70. Yeh CB, Hsieh MJ, Lin CW, Chiou HL, Lin PY, Chen TY and Yang SF: The antimetastatic effects of resveratrol on hepatocellular carcinoma through the downregulation of a metastasis-associated protease by SP-1 modulation. *PLoS One* 8: e56661, 2013.
71. Shankar S, Singh G and Srivastava RK: Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential. *Front Biosci* 12: 4839-4854, 2007.
72. Hong YB, Kang HJ, Kim HJ, Rosen EM, Dakshanamurthy S, Rondanin R, Baruchello R, Grisolia G, Daniele S and Bae I: Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. *Exp Mol Med* 41: 151-160, 2009.
73. Liu B, Zhou Z, Zhou W, Liu J, Zhang Q, Xia J, Liu J, Chen N, Li M and Zhu R: Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/S phase cell cycle arrest and apoptosis through caspase/cyclin CDK pathways. *Mol Med Rep* 10: 1697-1702, 2014.
74. Wang G, Guo X, Chen H, Lin T, Xu Y, Chen Q, Liu J, Zeng J, Zhang XK and Yao X: A resveratrol analog, phoyunbene B, induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. *Bioorg Med Chem Lett* 22: 2114-2118, 2012.
75. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, Shen HF and Xie LP: Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. *Cancer Sci* 101: 488-493, 2010.
76. Baribeau S, Chaudhry P, Parent S and Asselin É: Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. *PLoS One* 9: e86987, 2014.
77. Lin FY, Hsieh YH, Yang SF, Chen CT, Tang CH, Chou MY, Chuang YT, Lin CW and Chen MK: Resveratrol suppresses TPA-induced matrix metalloproteinase-9 expression through the inhibition of MAPK pathways in oral cancer cells. *J Oral Pathol Med* 44: 699-706, 2015.